The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal. But Bausch ...

Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward ...

His friend Henry Lomb invested his savings in Bausch's shop and in 1855 became his partner. Even with the loan, the business floundered until Bausch stumbled upon a piece of vulcanized rubber on a ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Bausch + Lomb, one of the world’s largest contact lens suppliers, is exploring a sale as a way to clean ...

The stock of eyecare company Bausch + Lomb Corp. was up 14%on Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its ...

It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products.

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...